News Medical on MSN1h
In silico docking of clinically approved drugs against the SARS-CoV-2 receptor-binding domainAnnouncing a new article publication for BIO Integration journal. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in China in December 2019, rapidly spread worldwide, ...
Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.
SAN ANTONIO, January 22, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early ...
SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW), a company specializing in noninvasive early-stage lung cancer diagnostics, announced today the acceptance of its patent ...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today ...
bioAffinity Technologie announced that the Australian Patent Office or IP Australia, has accepted bioAffinity’s patent application for the method of predicting the likelihood of lung cancer used ...
SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW), a company specializing in noninvasive early-stage lung cancer diagnostics, announced today the acceptance of its patent application ...
We demonstrate that scFv antibodies with both very high and low affinity to digoxigenin can ... electrophoresed on a 12% Laemmli gel using the Bio-Rad (Hercules, CA) mini-protean cell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback